



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: July 30, 2010

To: Primary Clinical Research Associates

From: Angie Patterson-LaBaw
Research Protocol Specialist

Re: N0747: A Randomized Phase II Trial of Sunitinib Plus Capecitabine Versus Capecitabine Alone (with the potential for crossover) for Elderly and/or Poor Performance Status Patients with Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction

Attached are updated form(s) for this protocol. Edits are as follows:

CRF Title	Brief Description of Edit
Nadir/Adverse Event Form	<ul style="list-style-type: none">Added "CTCAE v3.0" to CTC Adverse Event Term on all 6 pages
Baseline Adverse Events Form	<ul style="list-style-type: none">Added "CTCAE v3.0" to CTC Adverse Event Term on both pages

If you have any questions, please feel free to contact me.

Enclosure